

Level 2, 66 Hunter Street  
Sydney NSW 2000  
Tel: (61-2) 9300 3344  
Fax: (61-2) 9221 6333  
E-mail: [pnightingale@biotron.com.au](mailto:pnightingale@biotron.com.au)  
Website: [www.biotron.com.au](http://www.biotron.com.au)

22 June 2020

The Manager Companies  
ASX Limited  
20 Bridge Street  
SYDNEY NSW 2000

(2 pages by email)

Dear Madam,

**BIOTRON TO PRESENT LATEST BIT225 DATA AT INTERNATIONAL AIDS CONFERENCE**

The Directors are pleased to advise that Biotron Limited ('Biotron') will be presenting its latest BIT225 HIV-1 data at the 23rd International AIDS Conference (AIDS 2020: Virtual) in July 2020.

AIDS 2020: Virtual will bring together top basic, translational and clinical researchers from around the world to share the latest studies and developments in the ongoing battle against HIV/AIDS and other global infectious diseases including COVID-19.


Since completing the BIT225-009 Phase 2 HIV-1 clinical trial and releasing positive results in late 2018, Biotron has continued to characterise the unique mechanism of action of its lead anti-HIV-1 drug, BIT225. The Phase 2 trial and subsequent post-trial analyses demonstrated that BIT225 induces significant beneficial immunological changes. These may lead to boosting the body's immune system and eliminating virus reservoirs that persist despite treatment with conventional anti-HIV-1 drugs.

Biotron's latest data set to be presented at AIDS 2020: Virtual further extends previously reported studies of the mechanism of action of BIT225. The paper was accepted as a late breaker abstract for inclusion in the conference program.

Biotron is currently working with international HIV-1 experts to map out the next stage of development of BIT225. Data from these ongoing studies on the mechanism of action of BIT225 in modulating the immune system are central to positioning of the drug within the currently approved HIV-1 treatment landscape.

The Directors are also pleased to advise that chronic toxicology studies of BIT225 undertaken by a leading international contract research organisation have been completed. These six-month preclinical studies are important as they enable long-term dosing of BIT225 in future clinical studies in HIV-1 infected patients.

Yours sincerely



Peter J. Nightingale  
Company Secretary

pjn10386

## **About Biotron**

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need. The Company has BIT225 in clinical development for HIV-1 and a promising preclinical program for HBV. In addition, Biotron has several earlier stage programs designing drugs that target a class of virus protein known as viroporins which have a key role in the virus life cycle of a very broad range of viruses, many of which have caused worldwide health issues such as Coronavirus, Dengue, Ebola, Middle East Respiratory virus, Influenza and Zika viruses.

## **Enquiries**

Dr Michelle Miller  
Managing Director  
Biotron Limited  
+61-(0)412313329

Rudi Michelson  
Monsoon Communications  
+61-3 9620 3333